Back to Directory Molly Dyer Email mdyer@fhi360.org Phone 919-321-3851 Institution FHI 360 Title Community Programs Associate Request an Update Affiliated Studies IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy DAIDS Number 39052 Research Area Complications & Comorbidities Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy DAIDS Number 39052 Research Area Complications & Comorbidities Study Status In Development
